KNRS Stock Overview
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Kinarus Therapeutics Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF0.0042 |
52 Week High | CHF0.013 |
52 Week Low | CHF0.0002 |
Beta | 0 |
1 Month Change | -34.38% |
3 Month Change | 950.00% |
1 Year Change | -65.00% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -89.50% |
Recent News & Updates
Recent updates
Shareholder Returns
KNRS | CH Pharmaceuticals | CH Market | |
---|---|---|---|
7D | -12.5% | -0.8% | -0.1% |
1Y | -65.0% | -1.2% | 5.5% |
Return vs Industry: KNRS underperformed the Swiss Pharmaceuticals industry which returned -1.2% over the past year.
Return vs Market: KNRS underperformed the Swiss Market which returned 5.5% over the past year.
Price Volatility
KNRS volatility | |
---|---|
KNRS Average Weekly Movement | 91.1% |
Pharmaceuticals Industry Average Movement | 3.1% |
Market Average Movement | 3.4% |
10% most volatile stocks in CH Market | 7.8% |
10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: KNRS's share price has been volatile over the past 3 months.
Volatility Over Time: KNRS's weekly volatility has increased from 65% to 91% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | Alexander Bausch | https://www.kinarus.com |
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.
Kinarus Therapeutics Holding AG Fundamentals Summary
KNRS fundamental statistics | |
---|---|
Market cap | CHF4.49m |
Earnings (TTM) | CHF0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs KNRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KNRS income statement (TTM) | |
---|---|
Revenue | CHF0 |
Cost of Revenue | CHF0 |
Gross Profit | CHF0 |
Other Expenses | CHF0 |
Earnings | CHF0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did KNRS perform over the long term?
See historical performance and comparison